| Patients receiving 48 hours of treatment and a subgroup of patients with heart failure will be studied to
determine what effect bumetanide has on urine output (UOP). (HF) after 48 hours of therapy. A comparison of bumetanide
and furosemide potency was conducted using this subgroup. During therapy, electrolyte replacement was a secondary
safety objective. Methods: Study design: Among patients receiving bumetanide intermittently versus continuously, the
dose-response relationship was compared by measuring UOP per mg of drug received (mL/mg). An I.V. concomitant study
of bumetanide and furosemide was performed in a subset of patients with congestive heart failure on the basis of preexisting data. The safety of intravenous bumetanide was evaluated by quantifying electrolyte replacement during the study
period. Results: Intermittent (I.V) groups (n=46) achieved higher primary outcomes than continual (I.V) groups (n=8)
(P=0.001). For the intermittent I.V group and 24:1 for the continuous I.V group of patients with HF who received
furosemide (intermittent IV n=15, continuous IV n=13), we found a potency ratio of 31:1 and 24:1 for those who received
bumetanide (intermittent IV n=7, continuous IV n=2). Neither group replaced electrolytes significantly differently
Conclusion: When intermittent bumetanide was administered instead of continuous infusion, there was a greater response.
It is supported by this study that furosemide and bumetanide have equivalent dose equivalence ratios when administered
intravenously intermittently to patients with HFddd |
